To the editor:

Viral diseases are among the leading causes of morbidity and mortality in the world.[@bib1] A novel coronavirus, designated as COVID-19, recently emerged in Wuhan, China, at the end of 2019. As of March 5, 2020, there are \>95,000 reported cases of COVID-19 and \>3,000 deaths wordwide.[@bib2] Given the race against time, identifying drug treatment options as soon as possible is critical to adequately respond to the COVID-19 outbreak.[@bib3]

The "one drug, multiple viruses" paradigm came with the discovery of broad-spectrum antiviral agents, small molecules that inhibit a wide range of human viruses,[@bib1] and is even more pertinent today with outbreaks of Ebola, Zika, Dengue, influenza, and other viral infections, especially COVID-19. Because COVID-19 is 75% to 80% identical to the severe acute respiratory syndrome--CoV and even more closely related to several bat coronaviruses,[@bib4] potential treatment options against this emerging virus include as lopinavir/ritonavir, nucleoside analogues, neuraminidase inhibitors, remdesivir, fusion peptide (EK1), abidol, RNA synthesis inhibitors (such as tenofovir disoproxil fumarate \[TDF\], lamivudine \[3TC\]), interferon-α, and Chinese traditional medicine, such Shufengjiedu capsules and Lianhuaqingwen capsules, are. However, the efficacy and safety of these drugs for COVID-19 require confirmation by clinical experiments.[@bib3]

Chronic kidney disease (CKD) is frequently encountered in the general population and is a risk for increased viral morbidity. According to the U.S. Centers for Disease Control and Prevention, approximately 15% of U.S. adults (37 million people) are estimated to have CKD.[@bib5] During the first 2 months of the current outbreak in China, CKD was reported in 4.3% of the Chinese patients infected with COVID-19 who had severe presentation.[@bib6] End-stage kidney disease patients are a highly susceptible group with an infection rate of 16%, which exceeds that observed in other populations.[@bib7]

In the context of the epidemic or pandemic of COVID-19, these drugs will be prescribed to patients with CKD and/or end-stage kidney disease. Clinicians should thus be aware of the potential dosage adjustments and renal adverse events of those drugs in this patient group ([Table 1](#tbl1){ref-type="table"} ).Table 1Drug treatment options for COVID-19: potential kidney damage and dosage adjustment in CKD patientsCOVID-19 statusDosage according to glomerular filtration rateRenal adverse eventsNucleoside analogs FavipiravirPhase IINot available[a](#tbl1fna){ref-type="table-fn"}Not reported\
Potential mitochondrial toxicity RemdesivirPhase III GalidesivirAnimal AzvudinePhase II Ribavirin (in combination)Phase IIDosage adjustment according to standard recommendation\
Drug may be administered regardless of hemodialysis scheduleNot reported\
Hyperuricemia due to hemolytic anemiaNeuraminidase inhibitors Oseltamivir (in combination)Phase IVDosage adjustment according to standard recommendation\
Drug should be administered after dialysis session to avoid drug lossNot reportedFusion peptide inhibitor EK1Cell culture------HIV protease inhibitor Lopinavir/ritonavirPhase IV/IIIDrug should be administered at normal dosage and regardless of hemodialysis scheduleReversible AKI Danoprevir (in combination)Phase IVNot available[a](#tbl1fna){ref-type="table-fn"}Not reported Darunavir + cobicistatPhase II/IIIDrug may be administered at normal dosage and regardless of hemodialysis scheduleNephrolithiasis\
False creatinine level increaseMembrane fusion inhibitor UmifenovirPhase IVNot available[a](#tbl1fna){ref-type="table-fn"}Not reportedAminoquinoline family ChloroquinePhase IVDosage adjustment according to standard recommendation\
Drug should be administered after session on hemodialysis daysRenal lipidosis mimicking Fabry disease HydroxychloroquinePhase IIIRenal lipidosis mimicking Fabry disease\
False proteinuriaImmunotherapy CamrelizumabPhase IINot available[a](#tbl1fna){ref-type="table-fn"}Not yet reported\
Potential PDL-1 ligand-like renal toxicityMonoclonal antibodies AdalimumabPhase IVDrug should be administered at normal dosage[a](#tbl1fna){ref-type="table-fn"}Autoimmune GN (MN, IgA, lupus, ANCA vasculitis); granulomatous AIN TocilizumabPhase IVNot reported BevacizumabPhase II/IIIDrug should be administered at normal dosage and regardless of hemodialysis scheduleHT, proteinuria, TMA, GN, IN IFX-1 Anti C5aPhase IINot available[a](#tbl1fna){ref-type="table-fn"}Not reported LeronlimabPhase II REGN-3048, REGN-3051Phase I VelocImmune (Regeneron Technology, Tarrytown, NY)Phase IOthers Tenofovir alafenamidePhase IVDosage adjustment according to standard recommendation\
Drug should be administered after dialysis sessionAKI; proximal renal tubular acidosis ThalidomidePhase IIHyperkalemia IgPhase II/IIIDrug should be administered at normal dosage\
In the absence of hemodialysis clearance data, drug should be administered after session on hemodialysis daysAKI; osmotic nephrosis PirfenidonePhase IIINot available[a](#tbl1fna){ref-type="table-fn"}Not reported TranilastPhase IVNot reported FingolimodPhase IIDrug should be administered at normal dosage and regardless of hemodialysis scheduleTMA LeflunomidePhase IIIAnti-GBM GN; HT; tubular renal acidosis; TMA (in combination with methotrexate) Artemisinin piperaquinePhase IVNot available[a](#tbl1fna){ref-type="table-fn"}AKI; fatal acute hepatorenal failure[^1][^2]

Through this letter, we are not advocating any specific therapy and we support the notion that any therapy requires evaluation in a clinical trial. Furthermore, the rationale for providing this information to nephrologists is that we are likely to see off-label use of these drugs despite the absence of data, and we will need to provide input as to how the dosing should be modified in our patients with severely impaired kidney function.
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[^1]: COVID-19, novel coronavirus disease 2019; AIN, acute interstitial nephritis; AKI, acute kidney injury; ANCA, antineutrophil cytoplasmic antibody; CKD, chronic kidney disease; GN, glomerulonephritis; GBM, glomerular basement membrane; HT, hypertension; IN, interstitial nephritis; MN, membranous nephropathy; PDL-1, programmed death ligand 1; TMA, thrombotic microangiopathy.

[^2]: In the absence of hemodialysis clearance data, drug should be administered after session on hemodialysis days.
